- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06322589
Evaluation of Human Efficacy of SOD Like Super Drink
March 14, 2024 updated by: TCI Co., Ltd.
To assess the efficacy of SOD like Super Drink on anti-oxidant capacity, immuno regulation and skin for human
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ping Lin
- Phone Number: +886-02-879778111
- Email: candice.lin@tci-bio.com
Study Contact Backup
- Name: Hsiu-Mei Chiang
- Phone Number: 5302 +886-04-22053366
- Email: hmchiang@mail.cmu.edu.tw
Study Locations
-
-
-
Taichung City, Taiwan, 406040
- Recruiting
- China Medical University of department of cosmeceutics
-
Contact:
- Ping Lin
- Phone Number: +886-02-879778111
- Email: candice.lin@tci-bio.com
-
Contact:
- Hsiu-Mei Chiang, Ph.D.
- Phone Number: 5302 +886-04-22053366
- Email: hmchiang@mail.cmu.edu.tw
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- healthy adults aged between 30-65 years old
Exclusion Criteria:
- Subjects who have known cosmetic, drug or food allergies, difficulty in digestive tract absorption or disorder
- Patients with diseases of the skin, liver, kidney.
- Female who is pregnant or nursing or planning to become pregnant during the course of the study.
- Received facial laser therapy, chemical peeling or UV overexposure (> 3 hr/week) in the past 4 weeks.
- Students who are currently taking courses taught by the principal investigator of this trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo drink
|
consume 1 bottle per day
|
Experimental: SOD like Super Drink
|
consume 1 bottle per day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the volume of skin wrinkles
Time Frame: Volume change from Baseline skin wrinkles at 8 weeks
|
IRV full-face skin analyzer was utilized to measure skin wrinkles.
Units: arbitrary units
|
Volume change from Baseline skin wrinkles at 8 weeks
|
the roughness of skin texture
Time Frame: Rating skin roughness from Baseline skin texture at 8 weeks
|
IRV full-face skin analyzer was utilized to measure skin texture.
Units: arbitrary units
|
Rating skin roughness from Baseline skin texture at 8 weeks
|
the change of skin elasticity
Time Frame: Change from Baseline skin elasticity at 8 weeks
|
Cutometer® was utilized to measure skin elasticity.
Units: arbitrary units
|
Change from Baseline skin elasticity at 8 weeks
|
the change of Total Anti-oxidative Capacity (TAC) of blood
Time Frame: Change from Baseline TAC at 8 weeks
|
venous blood was sampled to measure TAC
|
Change from Baseline TAC at 8 weeks
|
the change of Superoxide Dismutase (SOD) of blood
Time Frame: Change from Baseline SOD at 8 weeks
|
venous blood was sampled to measure SOD
|
Change from Baseline SOD at 8 weeks
|
the change of Glutathione S-transferase (GST) of blood
Time Frame: Change from Baseline GST at 8 weeks
|
venous blood was sampled to measure GST
|
Change from Baseline GST at 8 weeks
|
the change of Glutathione (GSH) of blood
Time Frame: Change from Baseline GSH at 8 weeks
|
venous blood was sampled to measure GSH
|
Change from Baseline GSH at 8 weeks
|
the change of Malondialdehyde (MDA) of blood
Time Frame: Change from Baseline MDA at 8 weeks
|
venous blood was sampled to measure MDA
|
Change from Baseline MDA at 8 weeks
|
the change of immune-related cytokines of blood
Time Frame: Change from Baseline immune-related cytokines at 8 weeks
|
venous blood was sampled to measure immune-related cytokines
|
Change from Baseline immune-related cytokines at 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the change of skin surface hydration
Time Frame: Change from Baseline skin surface hydration at 8 week
|
Corneometer® CM 825 was utilized to measure skin surface hydration.
Units: arbitrary units
|
Change from Baseline skin surface hydration at 8 week
|
the change of skin Transepidermal Water Loss (TEWL)
Time Frame: Change from Baseline TEWL at 8 week
|
Tewameter® TM 300 was utilized to measure TEWL.
Units: arbitrary units
|
Change from Baseline TEWL at 8 week
|
the change of Skin Melanin Index
Time Frame: Change from Baseline skin Melanin Index at 8 week
|
Mexameter® MX 18was utilized to measure Melanin Index.
Units: arbitrary units
|
Change from Baseline skin Melanin Index at 8 week
|
the change of Skin Erythema Index
Time Frame: Change from Baseline skin Erythema Index at 8 week
|
Mexameter® MX 18was utilized to measure skin Erythema Index.
Units: arbitrary units
|
Change from Baseline skin Erythema Index at 8 week
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change of liver function biomarkers (AST, ALT) of blood
Time Frame: Change from Baseline liver function biomarkers at 8 weeks
|
Venous blood was sampled to measure liver function biomarkers
|
Change from Baseline liver function biomarkers at 8 weeks
|
The change of renal function biomarkers (creatinine, BUN) of blood
Time Frame: Change from Baseline renal function biomarkers at 8 weeks
|
Venous blood was sampled to measure renal function biomarkers
|
Change from Baseline renal function biomarkers at 8 weeks
|
The change of self-assessment skin condition and immuno condition
Time Frame: Change from Baseline skin condition and immunol condition at 8 weeks
|
A self-assessment questionnaire was collected to evaluate skin condition and immunol condition,As for the evalutation of skin condition ,the higher score the better;As for evaluation of immunol condition , the higher score the worse
|
Change from Baseline skin condition and immunol condition at 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Hsiu-Mei Chiang, China Medical University of department of cosmeceutics
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2024
Primary Completion (Estimated)
October 31, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
February 29, 2024
First Submitted That Met QC Criteria
March 14, 2024
First Posted (Actual)
March 21, 2024
Study Record Updates
Last Update Posted (Actual)
March 21, 2024
Last Update Submitted That Met QC Criteria
March 14, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CMUH112-REC3-175
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dermatology
-
Northwestern UniversityCompleted
-
Syneron MedicalCompletedAesthetic DermatologyUnited States
-
Kylane LaboratoiresEurofins Dermscan PharmascanNot yet recruitingAesthetic DermatologySwitzerland
-
Northwestern UniversityCompletedDermatology/Skin - OtherUnited States
-
Northwestern UniversityCompleted
-
Joanneum Research Forschungsgesellschaft mbHCompletedDermal Pharmacokinetic Measurements | Dermatology/Skin - OtherAustria
-
University Hospitals Coventry and Warwickshire...University Hospital, GenevaTerminatedTopical Corticosteroid-treated Dermatology Patients | Intra-ocular PressureUnited Kingdom
-
Istituto Ganassini S.p.A. di Ricerche BiochimicheRecruiting
-
Kylane LaboratoiresEurofins Dermscan PharmascanRecruitingAesthetic DermatologySwitzerland
-
University of ArizonaCompletedDermatology/Skin - OtherUnited States
Clinical Trials on placebo drink
-
Virginia Polytechnic Institute and State UniversityCompletedCardiovascular Risk FactorUnited States
-
University of the PacificCompletedCardiovascular DiseasesUnited States
-
Maastricht University Medical CenterTop Institute Food and NutritionCompletedMuscle Loss in ElderlyNetherlands
-
Mayo ClinicCompletedCardiovascular System | Hemodynamics | Energy DrinksUnited States
-
Wageningen UniversityMaastricht University Medical Center; Top Institute Food and NutritionCompleted
-
University of LimerickCompleted
-
University of LeedsArla FoodsCompletedCognitive Performance (Focus)United Kingdom
-
TCI Co., Ltd.Active, not recruiting